![]() |
|
|
Vol. 27, Issue 11, 1306-1308, November 1999
Department of Pharmacology, We investigated the catalysis of drug monooxygenation by human
embryonic hepatic tissues at a very early stage of gestation (days
52-59). Imipramine was used as a model substrate and the metabolites
generated were identified and quantified by electrospray mass
spectroscopy and HPLC. The primary metabolite generated was desipramine. It was reported previously from this and other
laboratories that cytochrome P-450 monooxygenase (CYP) 1A1, 1B1,
2E1, and 3A7 are each expressed in human embryonic hepatic tissues, and
selective inhibitors were therefore used to elucidate their respective
roles. Furafylline did not inhibit the reaction, supporting that CYP1A2 was not expressed in human embryonic hepatic tissues.
Diethyldithiocarbamate also failed to inhibit the same reaction,
suggesting that CYP2E1 did not play a significant role in catalyzing
the reaction. Triacetyloleandomycin inhibited the reaction by
approximately 90%, suggesting that CYP3A7 was primarily responsible
for catalyzing the reaction. However,
-naphthoflavone inhibited the
same reaction by approximately 70%, suggesting that CYP1A1 and/or
CYP1B1 may also catalyze the reaction substantially. To explore this
issue more, a cDNA-expressed human CYP3A7 (CYP3A7 SUPERSOMES) was
incubated with
-naphthoflavone (1 µM). Generation of desipramine
was inhibited by approximately 40 to 50%. The addition of the CYP3A
subfamily selective inhibitor triacetyloleandomycin (1 µM) produced
no statistically significant inhibition in reactions catalyzed by
CYP1A1 or 1B1 SUPERSOMES. Taken together, the results indicated that
CYP3A7 was the major if not sole isoform responsible for catalysis of
the N-demethylation of imipramine in human hepatic
tissues during embryogenesis.
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics